Cargando…

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamieh, Lana, Choueiri, Toni K., Ogórek, Barbara, Khabibullin, Damir, Rosebrock, Daniel, Livitz, Dimitri, Fay, Andre, Pignon, Jean-Christophe, McDermott, David F., Agarwal, Neeraj, Gao, Wenhua, Signoretti, Sabina, Kwiatkowski, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181431/ https://www.ncbi.nlm.nih.gov/pubmed/30256787 http://dx.doi.org/10.1371/journal.pgen.1007679

Ejemplares similares

From rapalogs to anti-aging formula
por: Blagosklonny, Mikhail V.
Publicado: (2017)

Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury
por: Petrache, Irina, et al.
Publicado: (2021)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
por: Valianou, Matthildi, et al.
Publicado: (2019)

Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
por: Shi, Guoli, et al.
Publicado: (2022)

In Reply
por: de Velasco, Guillermo, et al.
Publicado: (2017)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using (64)Cu-bevacizumab ImmunoPET
por: Chang, Albert J., et al.
Publicado: (2013)

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
por: Watari, Kosuke, et al.
Publicado: (2016)

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
por: Posada, Itziar M.D., et al.
Publicado: (2017)

The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19
por: Bischof, Evelyne, et al.
Publicado: (2021)

Landscape of tumor-infiltrating T cell repertoire of human cancers
por: Li, Bo, et al.
Publicado: (2016)

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
por: Tripathi, Abhishek, et al.
Publicado: (2020)

Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma
por: Priolo, Carmen, et al.
Publicado: (2018)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate
por: Pignon, Jean-Christophe, et al.
Publicado: (2015)

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis
por: Sasongko, Teguh Haryo, et al.
Publicado: (2015)

Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy
por: Guan, Yidi, et al.
Publicado: (2020)

Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R
por: Filippakis, Harilaos, et al.
Publicado: (2017)

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy
por: Martin, Nikolas T., et al.
Publicado: (2023)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
por: Liu, Heng-Jia, et al.
Publicado: (2023)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma
por: Saliby, Renee Maria, et al.
Publicado: (2023)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

From Sprouting Angiogenesis to Erythrocytes Generation by Cancer Stem Cells: Evolving Concepts in Tumor Microcirculation
por: Alameddine, Raafat S., et al.
Publicado: (2014)

Nipple angiofibromas with loss of TSC2 are associated with tuberous sclerosis complex
por: Nathan, Neera, et al.
Publicado: (2015)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Identification of ALK Gene Alterations in Urothelial Carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2014)

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
por: Fay, André P, et al.
Publicado: (2015)

Cancer-Related Pain: Prevalence, Severity and Management in a Tertiary Care Center in the Middle East
por: Hamieh, Nadine M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sl86f82uae43gmutrl7gu2r4g9